AdaptHealth
AHCO
6.06
-0.01
-0.08%
AdaptHealth
US · AHCO
#3414 by market cap
6.06
-0.01
-0.08%
Live - 5344 symbols - heartbeat 145s ago
· 2026-10-09 19:30
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is 0.87, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year -0.49% YoY
Margins
- Gross margin
- 18.77%
- Operating margin
- 5.74%
- Net margin
- -2.18%
Key ratios & quality
- Enterprise valuei
- 2.50B
- Altman Z-Scorei
- 0.87
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 529.64M | 1.06B | 2.45B | 2.97B | 3.20B | 3.26B | 3.24B |
| Gross profit | -- | 88.94M | 157.79M | 445.61M | 580.12M | 624.07M | 681.09M | 609.20M |
| Selling & admin expenses | 1.04M | 56.49M | 89.35M | 167.51M | 324.81M | 334.59M | 359.24M | 382.29M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | -1.23M | 29.38M | 71.35M | 225.61M | 190.41M | 232.39M | 276.81M | 186.27M |
| Pretax profit | 2.92M | -21.86M | -206.04M | 190.96M | 97.90M | -723.78M | 136.02M | -15.15M |
| Tax | 829.81K | 739.00K | -11.96M | 32.81M | 24.77M | -49.00M | 41.24M | 50.88M |
| Net profit | 2.09M | -22.60M | -194.09M | 158.15M | 73.13M | -674.78M | 94.78M | -66.04M |
| Basic EPS | 0 | -1 | -3 | 1 | 0 | -5 | 1 | -1 |
| Diluted EPS | 0.07 | -0.95 | -3.08 | 0.67 | 0.33 | -5.31 | 0.61 | -0.52 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 777.88M | 657.10M | 820.31M | 846.29M | 819.80M | 740.31M |
| Gross profit | -76.97M | -28.64M | -55.74M | 795.82M | -93.98M | -68.57M |
| Selling & admin expenses | 86.85M | 95.26M | 84.71M | 128.09M | 95.91M | 96.09M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 23.17M | 33.47M | 67.13M | 34.14M | 5.49M | 165.00K |
| Pretax profit | -5.23M | 38.16M | 36.35M | -97.99M | -20.11M | -165.33M |
| Tax | 850.00K | 32.78M | 10.60M | 3.54M | -5.23M | -21.23M |
| Net profit | -6.08M | 15.83M | 25.75M | -101.54M | -14.87M | -132.72M |
| Basic EPS | 0 | 0 | 0 | -1 | 0 | -1 |
| Diluted EPS | -0.05 | 0.10 | 0.16 | -0.76 | -0.12 | -0.99 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 1.11M | 181.42M | 363.25M | 670.06M | 585.31M | 649.02M | 755.79M | 728.90M |
| Cash & ST investments | 947.10K | 76.88M | 99.96M | 149.63M | 46.27M | 77.13M | 109.75M | 106.14M |
| Inventory | -- | 13.24M | 58.78M | 123.10M | 127.75M | 113.64M | 139.84M | 151.25M |
| Total assets | 254.12M | 546.54M | 1.81B | 5.25B | 5.22B | 4.51B | 4.49B | 4.32B |
| Total current liabilities | 699.39K | 154.05M | 422.05M | 499.81M | 456.21M | 537.00M | 566.99M | 712.39M |
| Short-term debt | -- | 21.47M | 30.43M | 66.86M | 67.21M | 91.76M | 60.51M | 68.74M |
| Long-term debt | -- | 395.11M | 776.57M | 2.18B | 2.15B | 2.09B | 1.96B | 1.72B |
| Total liabilities | 8,574,393.00 | 612,321,000.00 | 1,532,627,000.00 | 3,183,795,000.00 | 3,061,829,000.00 | 3,041,981,000.00 | 2,908,829,000.00 | 2,790,253,000.00 |
| Total equity | 245.55M | -65.78M | 280.85M | 2.07B | 2.16B | 1.47B | 1.58B | 1.53B |
| Retained earnings | 2.09M | -40.26M | -199.20M | -43.02M | 26.30M | -652.60M | -562.18M | -632.97M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 745.17M | 658.00M | 724.82M | 728.90M | 687.48M | 797.48M |
| Cash & ST investments | 53.65M | 68.63M | 80.36M | 106.14M | 47.96M | 43.29M |
| Inventory | 129.30M | 148.85M | 149.09M | 151.25M | 159.27M | 105.48M |
| Total assets | 4.44B | 4.35B | 4.38B | 4.32B | 4.42B | 4.34B |
| Total current liabilities | 576.73M | 622.09M | 670.70M | 712.39M | 743.29M | 709.21M |
| Short-term debt | 60.89M | 59.69M | 60.14M | 68.74M | 78.27M | 63.49M |
| Long-term debt | 1.94B | 1.79B | 1.74B | 1.72B | 1.80B | 1.88B |
| Total liabilities | 2,863,496,000.00 | 2,756,699,000.00 | 2,758,672,000.00 | 2,790,253,000.00 | 2,909,526,000.00 | 2,954,613,000.00 |
| Total equity | 1.57B | 1.59B | 1.62B | 1.53B | 1.51B | 1.39B |
| Retained earnings | -569.39M | -554.71M | -530.20M | -632.97M | -649.01M | -782.94M |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -1.63M | 60.42M | 195.63M | 275.68M | 373.87M | 480.67M | 541.84M | 601.77M |
| Depreciation & amortization | -- | 62.57M | 82.45M | 258.05M | 351.18M | 382.78M | 365.33M | 381.93M |
| Free cash flow | -1.63M | 39.09M | 155.88M | 72.37M | -17.56M | 143.20M | 235.78M | 219.38M |
| Dividends paid | -- | -250.00M | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 250.00M | 101.29M | 323.33M | 278.85M | -13.99M | -29.28M | 0 | 0 |
| Ending cash balance | 947.10K | 76.88M | 99.96M | 149.63M | 46.27M | 77.13M | 109.75M | 106.14M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 95.53M | 161.99M | 161.07M | 183.18M | 93.72M | 145.30M |
| Depreciation & amortization | 94.35M | 92.36M | 97.72M | 97.51M | 106.47M | 120.30M |
| Free cash flow | -58.00K | 73.33M | 66.82M | 79.29M | -27.49M | -20.94M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -- | -- | -- | -- |
| Ending cash balance | 53.65M | 68.63M | 80.36M | 106.14M | 47.96M | 43.29M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 1.70 | -12.98 | -31.94 | 11.43 | 3.01 | -37.62 | 5.46 | -4.58 |
| ROA %i | 1.64 | -3.75 | -5.47 | 4.01 | 1.21 | -13.96 | 1.84 | -1.61 |
| ROIC %i | -0.72 | 2.57 | -3.69 | 7.80 | 3.26 | -13.54 | 4.59 | 0.36 |
| 5-year avg ROE %i | -- | -- | -- | -- | -21.30 | -29.16 | -23.94 | -4.40 |
| EBIT margin %i | -- | 5.21 | -2.77 | 11.66 | 6.98 | -18.55 | 8.06 | 2.79 |
| FCF / sales %i | -- | 7.38 | 14.76 | 2.95 | -- | 4.47 | 7.23 | 6.76 |
| Current ratioi | 1.58 | 1.18 | 0.86 | 1.34 | 1.28 | 1.21 | 1.33 | 1.02 |
| Quick ratioi | 1.35 | 1.01 | 0.64 | 1.02 | 0.89 | 0.87 | 0.91 | 0.67 |
| Debt / assetsi | -- | 76.22 | 44.50 | 45.15 | 44.62 | 50.89 | 47.48 | 44.08 |
| LT debt / equityi | -- | -- | 218.82 | 111.73 | 105.13 | 151.04 | 131.74 | 120.78 |
| Interest coveragei | -- | 0.70 | -0.71 | 3.01 | 1.89 | -4.55 | 2.07 | 0.86 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | 77.67 | 44.69 | 9.93 | 2.99 |
| Net income CAGR (3Y) %i | -- | -- | -- | 321.46 | -- | -- | -16.65 | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -2.79 | 48.25 | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 5.13 | 4.80 | 4.81 | -4.58 | -5.18 | -15.39 |
| ROA %i | 1.74 | 1.66 | 1.70 | -1.61 | -1.80 | -5.25 |
| ROIC %i | 4.43 | 4.59 | 4.52 | 0.36 | -0.50 | -3.72 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 7.63 | 8.21 | 8.14 | 2.79 | 2.22 | -3.97 |
| FCF / sales %i | 8.46 | 7.13 | 6.56 | 6.76 | 5.85 | 2.92 |
| Current ratioi | 1.29 | 1.06 | 1.08 | 1.02 | 0.92 | 1.12 |
| Quick ratioi | 0.82 | 0.74 | 0.69 | 0.67 | 0.59 | 0.61 |
| Debt / assetsi | 47.40 | 44.82 | 43.43 | 44.08 | 45.22 | 47.57 |
| LT debt / equityi | 130.27 | 119.09 | 114.04 | 120.78 | 127.56 | 145.20 |
| Interest coveragei | 2.02 | 2.27 | 2.38 | 0.86 | 0.71 | -1.31 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Sleep Health is the largest reported line at 52.20% of revenue, across 3 reported segments.
- Respiratory health follows at 26.26%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Sleep Health52.20%
Respiratory health26.26%
Wellness at Home21.54%
Quote time 2026-10-09 19:30:04 · For reference only, not investment advice and not tailored to your situation.
AdaptHealth discussion 0 comments